Ticlopidine

Ticlopidine

Clinical data
Pregnancy category	AU: B1 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	B01AC05 (WHO)
Pharmacokinetic data
Bioavailability	>80%
Protein binding	98%
Metabolism	Hepatic
Elimination half-life	12 hours (single dose) 4 to 5 days (after repeated dosing)
Excretion	Renal and fecal
Identifiers
IUPAC name 3-[(2-chlorophenyl)methyl] -7-thia-3-azabicyclo[4.3.0] nona-8,10-diene
CAS Number	55142-85-3
PubChem CID	5472
DrugBank	APRD01257
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H14ClNS
Molar mass	263.786 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250mg twice daily by the oral route.

Action

• Inihibits platelet aggregation by altering the function of platelet membranes.
• Prolongs bleeding time.
• Decreased incidence of stroke in high-risk patients.

Contraindications

• Hypersensitivity
• Bleeding disorders
• Active bleeding
• Severe liver disease

Precautions

• Risk of bleeding (trauma, surgery, history of peptic ulcer disease)
• Renal or hepatic impairment
• Geriatric patients (increased sensitivity)
• Pregnancy, lactation, or children under 18

de:Ticlopidin it:Ticlopidina

Template:WikiDoc Sources